Zealand Pharma completes Phase 3 clinical program for HypoPal® rescue pen, initiates a new Phase 2 clinical proof of concept trial with dasiglucagon, and secures DKK 560 million in additional investment
![](http://www.globenewswire.com/Attachment/LogoDisplay/609173?filename=609173.jpg&size=1)
Company announcement – No. 38 / 2019Zealand Pharma completes Phase 3 clinical program for HypoPal®rescue pen, initiates a new Phase 2 clinical proof of concept trial with dasiglucagon, and secures DKK 560 million in additional investment